Reviewed by The Peptide Dispatch Editorial Team · Last reviewed July 6, 2026
MOTS-c (MOTSC) is a metabolic peptide, at the preclinical stage in the published literature. Mitochondria-derived peptide that regulates metabolic homeostasis and has shown effects on insulin sensitivity and fat metabolism.
Mitochondria-derived peptide that regulates metabolic homeostasis and has shown effects on insulin sensitivity and fat metabolism.
| Research Status | Preclinical |
|---|---|
| Half-Life | Unknown |
| Administration | Subcutaneous injection |
| Doses Reported in Published Studies | 5-10 mg weekly |
Activates AMPK pathway, improves glucose regulation, enhances mitochondrial function and metabolic flexibility.
Mitochondria-derived peptide that regulates metabolic homeostasis and has shown effects on insulin sensitivity and fat metabolism.
Activates AMPK pathway, improves glucose regulation, enhances mitochondrial function and metabolic flexibility.
MOTS-c is at the following stage in the published literature: Preclinical. All information is for research and educational purposes only.
Reported half-life: Unknown.
Reported administration route in the literature: Subcutaneous injection. This is not a recommendation for human use.
Educational content, not medical advice. Effects described are drawn from cited research in study subjects.